Table 1.
Clinical and pathological characteristics of patients with tumors tested for 1p/19q by FISH
| Characteristics | Total | 1p/19q Loss without Polysomy | 1p/19q Loss with >30% Polysomy | 1p/19q Loss with <30% Polysomy | 1p/19q Maintenance without Polysomy | 1p/19q Maintenance with Polysomy | P-Value |
|---|---|---|---|---|---|---|---|
| N = 412, 100% | N = 138, 33% | N = 150, 36% | N = 45, 11% | N = 49, 12% | N = 30, 7% | ||
| Age, y | |||||||
| Median | 43 | 42 | 45 | 44 | 43 | 44 | 0.82+ |
| Range | 11–86 | 11–86 | 15–83 | 21–82 | 17–72 | 23–79 | |
| Sex, n | |||||||
| Male | 227 (55%) | 68 (49%) | 92 (61%) | 24 (53%) | 24 (49%) | 19 (63%) | 0.21++ |
| Female | 185 (45%) | 70 (51%) | 58 (39%) | 21 (47%) | 25 (51%) | 11 (37%) | |
| Pathology diagnosis, n | |||||||
| Oligodendroglioma | 365 (89%) | 127 (92%) | 137 (91%) | 31 (69%) | 43 (88%) | 27 (90%) | |
| Oligoastrocytoma | 47 (11%) | 11 (8%) | 13 (9%) | 14 (31%) | 6 (12%) | 3 (10%) | <0.001 |
| WHO grade, n | |||||||
| Anaplastic (WHO grade III) | 232 (56%) | 61 (44%) | 110 (73%) | 19 (42%) | 29 (59%) | 13 (43%) | <0.001 |
| Not anaplastic (WHO grade II) | 180 (44%) | 77 (56%) | 40 (27%) | 26 (58%) | 20 (41%) | 17 (57%) | |
| IDH1/2 mutation, n | |||||||
| Positive | 130 (32%) | 42 (30%) | 65 (43%) | 14 (31%) | 6 (12%) | 3 (10%) | <0.01++ |
| Negative | 15 (3%) | 4 (3%) | 4 (3%) | 1 (2%) | 4 (8%) | 2 (7%) | |
| Unknown | 267 (65%) | 92 (67%) | 81 (54%) | 30 (67%) | 39 (80%) | 25 (83%) | |
| Ki67 scores, n | |||||||
| Median | 10 | 8 | 12 | 9.5 | 10 | 9 | 0.20+ |
| Range | 0.3–71.6 | 1–71.6 | 0.3–67.2 | 1–25.3 | 1.24–31 | 4.7–15 | |
| Location, n | |||||||
| Frontal | 257 (62%) | 97 (70%) | 100 (67%) | 29 (64%) | 19 (39%) | 12 (40%) | <0.001++ |
| Temporal | 73 (18%) | 13 (9%) | 27 (18%) | 7 (16%) | 19 (39%) | 7 (23%) | |
| Parietal | 41 (10%) | 11 (8%) | 15 (10%) | 6 (13%) | 5 (10%) | 4 (13%) | |
| Others | 7 (2%) | 4 (3%) | 0 | 0 | 2 (4%) | 1 (3%) | |
| Unknown | 34 (8%) | 13 (9%) | 8 (5%) | 3 (7%) | 4 (8%) | 6 (20%) | |
| Karnofsky Performance Status | |||||||
| Score | |||||||
| Median | 90 | 90 | 90 | 90 | 90 | 90 | |
| Range | 60–100 | 70–100 | 70–100 | 60–100 | 60–100 | 80–100 | |
| KPS Score Distribution, n | |||||||
| 60 | 2 (<1%) | 0 | 0 | 1 (2%) | 1 (2%) | 0 | 0.13++ |
| 70 | 5 (1%) | 1 (1%) | 1 (1%) | 1 (2%) | 2 (4%) | 0 | |
| 80 | 30 (7%) | 11 (8%) | 12 (8%) | 6 (13%) | 6 (12%) | 1 (3%) | |
| 90 | 70 (17%) | 24 (17%) | 34 (23%) | 5 (11%) | 5 (10%) | 1 (3%) | |
| 100 | 64 (16%) | 12 (9%) | 39 (26%) | 7 (33%) | 7 (14%) | 1 (3%) | |
| Unknown | 241 (59%) | 90 (65%) | 64 (43%) | 32 (71%) | 28 (57%) | 27 (90%) | |
| Initial surgery, n | |||||||
| GTR | 156 (38%) | 51 (37%) | 66 (44%) | 14 (31%) | 16 (33%) | 9 (30%) | 0.24++ |
| STR | 166 (40%) | 55 (40%) | 59 (39%) | 22 (49%) | 20 (41%) | 10 (33%) | |
| Biopsy | 62 (15%) | 22 (16%) | 15 (10%) | 7 (16%) | 10 (20%) | 8 (27%) | |
| Unknown | 28 (7%) | 10 (7%) | 10 (7%) | 2 (4%) | 3 (6%) | 3 (10%) | |
| Initial neoadjuvant/adjuvant chemotherapy, n | |||||||
| Yes | 229 (56%) | 78 (57%) | 90 (60%) | 18 (40%) | 29 (59%) | 14 (47%) | 0.07++ |
| No | 152 (37%) | 52 (38%) | 46 (31%) | 24 (53%) | 16 (33%) | 14 (47%) | |
| Unknown | 31 (7%) | 8 (6%) | 14 (9%) | 3 (7%) | 4 (8%) | 2 (6%) | |
| Initial radiotherapy, n | |||||||
| Yes | 174 (42%) | 55 (40%) | 58 (39%) | 14 (31%) | 33 (67%) | 14 (47%) | <0.001 ++ |
| No | 208 (50%) | 74 (54%) | 81 (54%) | 28 (62%) | 11 (22%) | 14 (47%) | |
| Unknown | 30 (7%) | 8 (5%) | 11 (7%) | 3 (7%) | 5 (10%) | 2 (6%) |
GTR: gross total resection; STR: subtotal resection. +One-way ANOVA analysis; ++ chi-square analysis.